@article{Patrick B. Walter_Eric A. Macklin_John Porter_Patricia Evans_Janet L. Kwiatkowski_Ellis J. Neufeld_Thomas Coates_Patricia J. Giardina_Elliott Vichinsky_Nancy Olivieri_Daniele Alberti_Jaymes Holland_Paul Harmatz_2008, place={Pavia, Italy}, title={Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial}, volume={93}, url={https://haematologica.org/article/view/4873}, DOI={10.3324/haematol.11755}, abstractNote={<strong>Background</strong> We assessed whether oxidant-stress and inflammation in β-thalassemia could be controlled by the novel oral iron chelator deferasirox as effectively as by deferoxamine.<strong>Design and Methods</strong> Forty-nine subjects were enrolled from seven sites and studied at baseline, and after 1, 6, and 12 months of therapy. Malondialdehyde, protein carbonyls, vitamins E and C, total non-transferrin bound iron, transferrin saturation, C-reactive protein, cytokines, serum ferritin concentration and liver iron concentration were measured.<strong>Results</strong> Liver iron concentration and ferritin declined significantly in both treatment groups during the study. This paralleled a significant decline in the oxidative-stress marker malondialdehyde (deferasirox −22%/year, deferoxamine −28%/year, average decline <em>p</em>=0.006). The rates of decline did not differ between treatment groups. Malondialdehyde was higher in both treatment groups than in a group of 30 non-thalassemic controls (<em>p</em><0.001). The inflammatory marker high-sensitivity C-reactive protein decreased significantly only in the group receiving deferasirox (deferasirox −51%/year, deferoxamine +8.5%/year, <em>p</em>=0.02). This result was confounded by a chance difference in the level of high-sensitivity C-reactive protein between the two groups at baseline, but analyses controlling for this difference suggested an equally large treatment effect.<strong>Conclusions</strong&gt; Iron chelation therapy with deferoxamine or with deferasirox was equally effective in decreasing iron burden and malondialdehyde. The possible differential effect of the two chelators on inflammation warrants further investigation.}, number={6}, journal={Haematologica}, author={Patrick B. Walter and Eric A. Macklin and John Porter and Patricia Evans and Janet L. Kwiatkowski and Ellis J. Neufeld and Thomas Coates and Patricia J. Giardina and Elliott Vichinsky and Nancy Olivieri and Daniele Alberti and Jaymes Holland and Paul Harmatz}, year={2008}, month={May}, pages={817-825} }